BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
Covered in this story
What has happened since
- Bridgebio Pharma Inc is down 14.8% since this was published, 80 days ago.
- Palo Alto Networks is up 2.2% since this was published, 80 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Bridgebio Pharma Inc
- Jefferies: $66.1 → $110 by Oct 2027 · Buy via Investing.com
- TD Cowen: $66.1 → $110 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BBIO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Bridgebio Pharma Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.